BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
暂无分享,去创建一个
H Tesch | D Hasenclever | M Sieber | A Engert | V. Diehl | J. Franklin | M. Pfreundschuh | B. Lathan | U. Paulus | D. Hasenclever | H. Tesch | J. Wolf | R. Hermann | M. Sieber | G. Wulf | H. Bischoff | A. Engert | V Diehl | A. Georgii | M Pfreundschuh | A Georgii | J. Rueffer | G Wulf | U Paulus | J Franklin | J Wolf | B Lathan | J U Rueffer | M Sextro | R Hermann | L Holmer | U Stappert-Jahn | E Winnerlein-Trump | S Krause | A Glunz | K von Kalle | H Bischoff | C Haedicke | E Duehmke | M Loeffler | S. Krause | M. Sextro | M. Loeffler | E. Duehmke | A. Glunz | C. Haedicke | L. Holmer | U. Stappert-Jahn | E. Winnerlein-Trump | K. von Kalle | Michael Pfreundschuh | Hans Tesch | Juergen Wolf | Gerald Wulf | Stefan W. Krause | K. V. Kalle | Helge Bischoff | Juergen Wolf
[1] G. Bonadonna,et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP , 1975, Cancer.
[2] Aisenberg Ac. MOPP, ABVD, or both to treat Hodgkin's disease. , 1993 .
[3] V. Diehl,et al. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] J. Connors,et al. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] G. Bonadonna,et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] S. Hancock,et al. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] D. Linch. Dose optimisation and dose intensification in malignant lymphoma. , 1994, European journal of cancer.
[8] V. Diehl,et al. Is there a rationale for high-dose chemotherapy as first line treatment of advanced Hodgkin's disease? German Hodgkin's Lymphoma Study Group (GHSG). , 1995, Leukemia & lymphoma.
[9] K. Maclennan,et al. Hybrid LOPP/EVA is not better than LOPP alternating with EVAP: a prematurely terminated British National Lymphoma Investigation randomized trial. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] E. Frei,et al. Dose: a critical factor in cancer chemotherapy. , 1980, The American journal of medicine.
[11] N. Schmitz,et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Flavio Crippa,et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] C. Croce,et al. Common region of ALL-1 gene disrupted in epipodophyllotoxin-related secondary acute myeloid leukemia. , 1993, Cancer research.
[14] K. Propert,et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. , 1992, The New England journal of medicine.
[15] J. Whitehead,et al. A FORTRAN program for the design and analysis of sequential clinical trials. , 1983, Computers and biomedical research, an international journal.
[16] A. Hagenbeek,et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] V. Devita,et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. , 1980, Annals of internal medicine.
[18] V. Diehl,et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] V. Diehl,et al. Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] L. Freedman. Tables of the number of patients required in clinical trials using the logrank test. , 1982, Statistics in medicine.
[21] S M Hubbard,et al. The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture. , 1987, Cancer research.
[22] R. D. Hunter,et al. WHO Handbook for Reporting Results of Cancer Treatment , 1980 .
[23] M Tubiana,et al. Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.
[24] K. Hübner,et al. Classification of Hodgkin's disease biopsies by a panel of four histopathologists. Report of 1,140 patients from the German National Trial. , 1993, Leukemia & lymphoma.
[25] A Tsodikov,et al. A cure model with time-changing risk factor: an application to the analysis of secondary leukaemia. A report from the International Database on Hodgkin's Disease. , 1998, Statistics in medicine.
[26] V. Diehl,et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] M. Pfreundschuh,et al. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease , 1995 .
[28] J. Armitage,et al. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.